Volume 7 , Issue 2 , August 2017 , Pages 205-210
Mohammad A. Al Sheikhani 1 ; Bnar Sardar Saida 2
1 Kurdistan Center for Gastrohepatology and Hepatology; Department of Medicine, College of Medicine, University of Sulaimani.
2 Shar Hospital, Directory of Health, Ministry of Health, Sulaimani, Iraqi Kurdistan, Iraq.
Background
Helicobacter pylori infection has a high global prevalence and carries a significant disease burden. For more than 10 years now, the recommended therapy worldwide for eradication has been a standard triple therapy with amoxicillin, clarithromycine and a proton pump inhibitor. The success of this therapy has been declined in the recent years due to many factors.
Objectives
To determine the efficacy of the current standard triple anti-Helicobacter pylori treatment in Slemani.
Patients and Methods
This is a prospective study enrolling 62 patients carried out at Shar teaching hospital endoscopy department during a period from January 2015 through January 2016. Patients with gastric and duodenal ulcer underwent biopsy taken from body and antrum of their stomach (one sample from each part), along with stool samples for monoclonal stool antigen testing. They were subjected to standard triple therapy for 2 weeks. After 4 weeks of completion of the treatment they underwent stool antigen test to confirm the eradication.
Results
The eradication rate was 58%. Male gender, smoking, diabetes and non-steroidal anti inflammatory dug use had reduced chance of cure.
Conclusion
The eradication rate was low in our locality for the standard triple therapy. Possibly due to many factors, including rising numbers of antibiotic resistance, smoking, poor compliance and comorbidities like diabetes mellitus.